Details of the Drug

General Information of Drug (ID: DMKXY2R)

Drug Name

Ibutilide

Synonyms

Corvert; Ibutilida; Ibutilidum; Butilide fumarate; IBUTILIDE FUMARATE; Ibutilide Fumarate [USAN]; U 70226E; U82208E; U82209E; Corvert (TN); Ibutilida [INN-Spanish]; Ibutilide (INN); Ibutilide [BAN:INN]; Ibutilide [INN:BAN]; Ibutilide fumarate (USAN); Ibutilidum [INN-Latin]; U-70226E; U-82208E; U-82209E; Ibutilide, (+-)-isomer; N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide; Ibutilide, fumarate salt (2:1), (+-)-isomer; N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide; N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide; Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-, (E)-2-butenedioate (2:1) (salt); Methanesulfonamide, N-(4-(4-(ethylheptylamino)-1-hydroxybutyl)phenyl)-, (+-)-,(E)-2-butenedioate (2:1) (salt); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfoanilide (E)-2-butenedioate (2:1); (+-)-4'-(4-(Ethylheptylamino)-1-hydroxybutyl)methanesulfonanilide fumarate (2:1) (salt); (+-)-N-(4-(4-(Ethylheptylamino)-1-hydroxybutyl)phenyl)methanesulfonamide (E)-butenedioate

Indication

Disease Entry	ICD 11	Status	REF
Atrial fibrillation	BC81.3	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiarrhythmic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

384.6

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is rapid after intravenous injection []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance: The clearance of drug is 29 mL/min/kg []
Elimination: 7% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 hours (ranges from 2 - 12 h) [3]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3389 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.6% [3]
Vd: The volume of distribution (Vd) of drug is 11 L/kg []
Water Solubility: The ability of drug to dissolve in water is measured as 100 mg/mL [2]

Chemical Identifiers

Formula: C20H36N2O3S
IUPAC Name: N-[4-[4-[ethyl(heptyl)amino]-1-hydroxybutyl]phenyl]methanesulfonamide
Canonical SMILES: CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
InChI: InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3
InChIKey: ALOBUEHUHMBRLE-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 60753
ChEBI ID: CHEBI:5856
CAS Number: 122647-31-8
DrugBank ID: DB00308
TTD ID: D02MLW

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Modulator	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ibutilide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Adenosine	DMM2NSK	Major	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[6]
-----------

Coadministration of a Drug Treating the Disease Different from Ibutilide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[7]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Midostaurin.	Acute myeloid leukaemia [2A60]	[8]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Idarubicin.	Acute myeloid leukaemia [2A60]	[8]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Daunorubicin.	Acute myeloid leukaemia [2A60]	[8]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Arn-509.	Acute myeloid leukaemia [2A60]	[8]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[8]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Oliceridine.	Acute pain [MG31]	[9]
Terfenadine	DM4KLPT	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[8]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Tacrine.	Alzheimer disease [8A20]	[8]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Galantamine.	Alzheimer disease [8A20]	[8]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Rivastigmine.	Alzheimer disease [8A20]	[8]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Donepezil.	Alzheimer disease [8A20]	[8]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Ibutilide and Metronidazole.	Amoebiasis [1A36]	[10]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Ivabradine.	Angina pectoris [BA40]	[11]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Bepridil.	Angina pectoris [BA40]	[8]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Dronedarone.	Angina pectoris [BA40]	[8]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[8]
Hydroxyzine	DMF8Y74	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[8]
Promazine	DMZAL7W	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Promazine.	Appearance/behaviour symptom [MB23]	[8]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Cilostazol.	Arterial occlusive disease [BD40]	[8]
Voriconazole	DMAOL2S	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Voriconazole.	Aspergillosis [1F20]	[8]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Posaconazole.	Aspergillosis [1F20]	[8]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Levalbuterol.	Asthma [CA23]	[12]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Terbutaline.	Asthma [CA23]	[13]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Pirbuterol.	Asthma [CA23]	[13]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[8]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[8]
Ciprofloxacin XR	DM2NLS9	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[8]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[14]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Ibutilide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[8]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[15]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[8]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[8]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[8]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[8]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Telithromycin.	Bacterial infection [1A00-1C4Z]	[8]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Retigabine.	Behcet disease [4A62]	[8]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Loperamide.	Bowel habit change [ME05]	[16]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Eribulin.	Breast cancer [2C60-2C6Y]	[8]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Lapatinib.	Breast cancer [2C60-2C6Y]	[8]
Tamoxifen	DMLB0EZ	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Tamoxifen.	Breast cancer [2C60-2C6Y]	[8]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Toremifene.	Breast cancer [2C60-2C6Y]	[8]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Bosutinib.	Breast cancer [2C60-2C6Y]	[8]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Grepafloxacin.	Bronchitis [CA20]	[15]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Sotalol.	Cardiac arrhythmia [BC9Z]	[8]
Iodipamide	DMXIQYS	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Iodipamide.	Cholelithiasis [DC11]	[17]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Ibutilide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[8]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[12]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Oxaliplatin	DMQNWRD	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Oxaliplatin.	Colorectal cancer [2B91]	[8]
Levobupivacaine	DM783CH	Moderate	Increased risk of atrioventricular block by the combination of Ibutilide and Levobupivacaine.	Corneal disease [9A76-9A78]	[18]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Halothane.	Corneal disease [9A76-9A78]	[8]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Propofol.	Corneal disease [9A76-9A78]	[19]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Sevoflurane.	Corneal disease [9A76-9A78]	[8]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Probucol.	Coronary atherosclerosis [BA80]	[8]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Methadone.	Cough [MD12]	[8]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Clofazimine.	Crohn disease [DD70]	[8]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Mifepristone.	Cushing syndrome [5A70]	[8]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Pasireotide.	Cushing syndrome [5A70]	[8]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Osilodrostat.	Cushing syndrome [5A70]	[8]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Sertraline.	Depression [6A70-6A7Z]	[8]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Trimipramine.	Depression [6A70-6A7Z]	[8]
Imipramine	DM2NUH3	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Imipramine.	Depression [6A70-6A7Z]	[8]
Fluoxetine	DM3PD2C	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Fluoxetine.	Depression [6A70-6A7Z]	[8]
Nortriptyline	DM4KDYJ	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Nortriptyline.	Depression [6A70-6A7Z]	[8]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Escitalopram.	Depression [6A70-6A7Z]	[8]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Clomipramine.	Depression [6A70-6A7Z]	[8]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Trazodone.	Depression [6A70-6A7Z]	[8]
Amitriptyline	DMK7F9S	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Amitriptyline.	Depression [6A70-6A7Z]	[8]
Amoxapine	DMKITQE	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Amoxapine.	Depression [6A70-6A7Z]	[8]
Mirtazapine	DML53ZJ	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Mirtazapine.	Depression [6A70-6A7Z]	[8]
Protriptyline	DMNHTZI	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Protriptyline.	Depression [6A70-6A7Z]	[8]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Doxepin.	Depression [6A70-6A7Z]	[8]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Maprotiline.	Depression [6A70-6A7Z]	[8]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[8]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Deutetrabenazine.	Dystonic disorder [8A02]	[8]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Ingrezza.	Dystonic disorder [8A02]	[8]
Diphenhydramine	DMKQTBA	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[10]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Solifenacin.	Functional bladder disorder [GC50]	[8]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Pentamidine.	Fungal infection [1F29-1F2F]	[8]
Ketoconazole	DMPZI3Q	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Ketoconazole.	Fungal infection [1F29-1F2F]	[8]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[8]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[8]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[22]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[8]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Crizotinib.	Lung cancer [2C25]	[8]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Ceritinib.	Lung cancer [2C25]	[8]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Osimertinib.	Lung cancer [2C25]	[8]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Selpercatinib.	Lung cancer [2C25]	[8]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Lumefantrine.	Malaria [1F40-1F45]	[10]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Halofantrine.	Malaria [1F40-1F45]	[23]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Chloroquine.	Malaria [1F40-1F45]	[24]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Hydroxychloroquine.	Malaria [1F40-1F45]	[24]
Quinine	DMSWYF5	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Quinine.	Malaria [1F40-1F45]	[8]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Primaquine.	Malaria [1F40-1F45]	[8]
Mefloquine	DMWT905	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Mefloquine.	Malaria [1F40-1F45]	[8]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[8]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[25]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Vemurafenib.	Melanoma [2C30]	[8]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Ibutilide and LGX818.	Melanoma [2C30]	[8]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Thalidomide.	Multiple myeloma [2A83]	[10]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Siponimod.	Multiple sclerosis [8A40]	[10]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Ozanimod.	Multiple sclerosis [8A40]	[26]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Romidepsin.	Mycosis fungoides [2B01]	[8]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[8]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[8]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Droperidol.	Nausea/vomiting [MD90]	[8]
Dimenhydrinate	DM264B3	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Dimenhydrinate.	Nausea/vomiting [MD90]	[10]
Prochlorperazine	DM53SRA	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Prochlorperazine.	Nausea/vomiting [MD90]	[8]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Promethazine.	Nausea/vomiting [MD90]	[8]
Palonosetron	DMBHMOX	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Palonosetron.	Nausea/vomiting [MD90]	[8]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Granisetron.	Nausea/vomiting [MD90]	[8]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Dolasetron.	Nausea/vomiting [MD90]	[8]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Ondansetron.	Nausea/vomiting [MD90]	[8]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Entrectinib.	Non-small cell lung cancer [2C25]	[8]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[11]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Lofexidine.	Opioid use disorder [6C43]	[8]
Dextropropoxyphene	DM23HCX	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Dextropropoxyphene.	Pain [MG30-MG3Z]	[10]
Prilocaine	DMI7DZ2	Moderate	Increased risk of atrioventricular block by the combination of Ibutilide and Prilocaine.	Pain [MG30-MG3Z]	[18]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Buprenorphine.	Pain [MG30-MG3Z]	[8]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Triclabendazole.	Parasitic worm infestation [1F90]	[8]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Pimavanserin.	Parkinsonism [8A00]	[8]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Apomorphine.	Parkinsonism [8A00]	[8]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[27]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Lefamulin.	Pneumonia [CA40]	[28]
Ritodrine	DM4V6RL	Major	Increased risk of ventricular arrhythmias by the combination of Ibutilide and Ritodrine.	Preterm labour/delivery [JB00]	[13]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Degarelix.	Prostate cancer [2C82]	[8]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Ibutilide and ABIRATERONE.	Prostate cancer [2C82]	[8]
Nilutamide	DMFN07X	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Nilutamide.	Prostate cancer [2C82]	[8]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Enzalutamide.	Prostate cancer [2C82]	[8]
Flutamide	DMK0O7U	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Flutamide.	Prostate cancer [2C82]	[8]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Relugolix.	Prostate cancer [2C82]	[8]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Bicalutamide.	Prostate cancer [2C82]	[8]
Alfuzosin	DMZVMKF	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Alfuzosin.	Prostate hyperplasia [GA90]	[8]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[8]
Fluphenazine	DMIT8LX	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Fluphenazine.	Psychotic disorder [6A20-6A25]	[8]
Triflupromazine	DMKFQJP	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Triflupromazine.	Psychotic disorder [6A20-6A25]	[8]
Sorafenib	DMS8IFC	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Sorafenib.	Renal cell carcinoma [2C90]	[8]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[8]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Quetiapine.	Schizophrenia [6A20]	[8]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Mesoridazine.	Schizophrenia [6A20]	[8]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Thioridazine.	Schizophrenia [6A20]	[8]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Aripiprazole.	Schizophrenia [6A20]	[10]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Iloperidone.	Schizophrenia [6A20]	[8]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Paliperidone.	Schizophrenia [6A20]	[8]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Haloperidol.	Schizophrenia [6A20]	[8]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Perphenazine.	Schizophrenia [6A20]	[8]
Chlorpromazine	DMBGZI3	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Chlorpromazine.	Schizophrenia [6A20]	[8]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Clozapine.	Schizophrenia [6A20]	[8]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Trifluoperazine.	Schizophrenia [6A20]	[8]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Risperidone.	Schizophrenia [6A20]	[8]
Olanzapine	DMPFN6Y	Moderate	Increased risk of prolong QT interval by the combination of Ibutilide and Olanzapine.	Schizophrenia [6A20]	[10]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Amisulpride.	Schizophrenia [6A20]	[10]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Asenapine.	Schizophrenia [6A20]	[8]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Pimozide.	Schizophrenia [6A20]	[11]
Mepivacaine	DMH2NMY	Moderate	Increased risk of atrioventricular block by the combination of Ibutilide and Mepivacaine.	Sensation disturbance [MB40]	[18]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Vardenafil.	Sexual dysfunction [HA00-HA01]	[8]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Ibutilide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[8]
Epirubicin	DMPDW6T	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[8]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[8]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[8]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[8]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Pitolisant.	Somnolence [MG42]	[8]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[8]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Lenvatinib.	Thyroid cancer [2D10]	[8]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Cabozantinib.	Thyroid cancer [2D10]	[8]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Papaverine.	Tonus and reflex abnormality [MB47]	[29]
Tizanidine	DMR2IQ4	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Tizanidine.	Tonus and reflex abnormality [MB47]	[8]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Tacrolimus.	Transplant rejection [NE84]	[8]
Astemizole	DM2HN6Q	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[8]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[10]
Bretylium	DM1FX74	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Bretylium.	Ventricular tachyarrhythmia [BC71]	[8]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[30]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[8]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Ibutilide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[8]
-----------


⏷ Show the Full List of 183 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7200).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
7	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
8	Canadian Pharmacists Association.
9	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
10	Cerner Multum, Inc. "Australian Product Information.".
11	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
13	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
14	Gitler B, Berger LS, Buffa SD "Torsades de pointes induced by erythromycin." Chest 105 (1994): 368-72. [PMID: 8306730]
15	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
16	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
17	Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98. [PMID: 15206999]
18	Keidar S, Grenadier E, Palant A "Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration." Am Heart J 104 (1982): 1384-5. [PMID: 7148661]
19	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
20	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
21	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
22	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
23	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
24	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
25	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
26	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
27	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
28	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
29	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
30	Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]